We elucidated 149 p38 inhibitors that can be tested through in vitro and in vivo experimental trials. With an average validation accuracy of 92% and area under the ROC curve of 0.97, model has shown significant efficacy in predicting the ability of a compound to inhibit p38. Furthermore, protein docking scores indicate that our predicted inhibitors statistically significantly better (Table ) than random FDA-approved molecules, and even slightly better than the top known p38-inhibitors. Following experimental trials, these compounds could be used as treatments for various p38-mediated diseases, including not just MFM, but also cancers and inflammatory diseases like rheumatoid arthritis and Alzheimer's. Furthermore, the procedure described in this study can be applied to repurpose existing drugs as protein inhibiting or activating treatments for a wide variety diseases.